GAMMA Investing’s ADC Therapeutics ADCT Stock Holding History

GAMMA Investing’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.86K	Buy	2,348 +2,299	+4,692%	+$2.69K	﹤0.01%	3852
2026 Q2	$52	Sell	49 -683	-93%	-$1.99K	﹤0.01%	4121
2026 Q1	$2.74K	Buy	732 +240	+49%	+$946	﹤0.01%	3567
2025 Q4	$1.74K	Buy	+492	New	+$2K	﹤0.01%	3646

Other funds holding ADCT

DIM

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

SCM

Saxony Capital Management St. Louis, Missouri $238M AUM 19.13% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing's ADCT Position: Q3 2026 in Review

GAMMA Investing increased its ADC Therapeutics (ADCT) stake by 4,692% in Q3 2026, buying an estimated $2.69K and bringing the position to 2,348 shares worth $2.86K. The position accounts for ﹤0.01% of the portfolio, ranked #3852.

GAMMA Investing first reported a position in ADCT in Q4 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

GAMMA Investing held 2,348 shares of ADC Therapeutics worth $2.86K as of Q3 2026.
GAMMA Investing bought 2,299 ADC Therapeutics shares in Q3 2026, an estimated $2.69K.
ADC Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3852 holding.
GAMMA Investing first reported a position in ADC Therapeutics in Q4 2025 and has held it in 4 quarters since.
8 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.